Atria Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Atria Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$458K	Sell	18,109 -1,336	-7%	-$29.4K	﹤0.01%	1572
2026 Q1	$433K	Sell	19,445 -2,557	-12%	-$61.1K	﹤0.01%	1523
2025 Q4	$588K	Buy	22,002 +4,386	+25%	+$105K	0.01%	1337
2025 Q3	$376K	Sell	17,616 -4,471	-20%	-$106K	﹤0.01%	1593
2025 Q2	$476K	Buy	22,087 +4,574	+26%	+$85K	0.01%	1450
2025 Q1	$291K	Buy	17,513 +4,111	+31%	+$74.7K	﹤0.01%	1632
2024 Q4	$246K	Sell	13,402 -11,035	-45%	-$178K	﹤0.01%	1694
2024 Q3	$376K	Buy	24,437 +2,384	+11%	+$39.8K	﹤0.01%	1483
2024 Q2	$358K	Buy	+22,053	New	+$356K	﹤0.01%	1482

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atria Investments's ACAD Position: Q2 2026 in Review

Atria Investments reduced its Acadia Pharmaceuticals (ACAD) stake by 6.9% in Q2 2026, selling an estimated $29.4K and leaving 18,109 shares worth $458K. The position accounts for ﹤0.01% of the portfolio, ranked #1572.

Atria Investments first reported a position in ACAD in Q2 2024 and has held it in 9 quarters since. The position peaked at $588K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Atria Investments held 18,109 shares of Acadia Pharmaceuticals worth $458K as of Q2 2026.
Atria Investments sold 1,336 Acadia Pharmaceuticals shares in Q2 2026, an estimated $29.4K.
Acadia Pharmaceuticals made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #1572 holding.
Atria Investments first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Atria Investments's Acadia Pharmaceuticals position peaked at $588K in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.